Add as a preferred source on GoogleNovo Nordisk Raises 2026 Outlook as Wegovy Pill Sales Reach DKK 5.394B
Adjusted sales reached DKK 79.195 billion, up 4% at constant exchange rates. Adjusted operating profit rose 27% at constant exchange rates to DKK 31.72 billion.
Novo Nordisk raised its 2026 outlook for sales and operating profit after its Wegovy pill generated DKK 5.394 billion in third-quarter sales across four markets, including the United States.
The company now expects adjusted sales and adjusted operating profit to each range from a 2% decline to 2% growth this year at constant exchange rates. Its previous outlook allowed declines of up to 6% or flat results for both measures. The improved outlook reflects higher expectations for GLP-1 product sales.
The pill was available in the United States, the United Arab Emirates, the United Kingdom and Germany by quarter-end. Four more launches afterward brought availability to eight markets.
Novo Nordisk's adjusted sales totaled DKK 79.195 billion in the quarter, up 4% at constant exchange rates. Adjusted operating profit rose 27% at constant exchange rates to DKK 31.72 billion.
Novo Nordisk was listed among companies scheduled to report in an earlier health care earnings calendar.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.